Archive News 2016 - 16 Dec 2016 – 21st Century Cures Act signed into law by President Obama - 30 Nov 2016 – Destiny Pharma CEO appointed to the board of GAMRIF - 31 Oct 2016 – Wellcome Trust report on boosting development of new antimicrobial drugs - Destiny Pharma to attend IDWeek in New Orleans, Louisiana - 21 Sep 2016 – Momentous Step taken by UN to Fight Antibiotic Resistance welcomed by Destiny Pharma - 05 Sep 2016 – Press Release: Novel Antibacterial Drug, exeporfinium chloride, Delivers Encouraging Safety, Tolerability and Efficacy Data in US Clinical Trial - Destiny Pharma Expert View Published in The Pharma Letter - Destiny Pharma invited to present at the inaugural Superbugs & Superdrugs USA Conference & Exhibition on the 14th and 15th November 2016 in New Jersey, USA - 19 May 2016 – Destiny Pharma Welcomes O’Neill Report on Tackling Antimicrobial Resistance (AMR) - 18 Mar 2016 – Destiny Pharma: ‘In the News.’ - 26 Jan 2016 – Destiny Pharma sign Declaration to fight antibiotic resistance 2015 - 11 Nov 2015 – Press Release: Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphyloccocal Infections - 22 Oct 2015 – G7 Health Minsters committed to tackle antimicrobial resistance - 06 Oct 2015 – BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance release first position paper identifying the key actions required to reinvigorate investment and R&D in the antibacterial field - 24 Aug 2015 – Latest figures from Public Health England show that the number of Methicillin Sensitive Staphylococcus aureus (MSSA) blood infection (bacteraemia) cases continue to rise in the UK - 23 Jun 2015 – Destiny Pharma participates in the launch of the Antibiotic Discovery Global Network - Destiny Pharma to attend the Society for Healthcare Epidemiology of America (SHEA) Spring 2015 Conference: Science Guiding Prevention in Orlando, Florida - Destiny Pharma invited to present at the inaugural Pipeline Corner event to be held during the 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting in Copenhagen, Denmark on the 25-28th April 2015 - 05 Feb 2015 – Global Innovation Fund recommended to be set up to support new ideas to combat antimicrobial resistance - 08 Jan 2015 – Destiny Pharma to attend DRIVE-AB (Driving reinvestment in R&D and the responsible use of antibiotics) meeting in London on February 9th 2014 - 19 Dec 2014 – Drug-resistant superbugs could cost up to $100 trillion and cause 10 million extra deaths a year by 2050 - 05 Dec 2014 – Destiny Pharma invited to attend the first event of the Review on Antimicrobial Resistance Meeting chaired by Jim O’Neill and hosted by the Wellcome Trust on the 11th December 2014 - 17 Nov 2014 – Antibiotic Awareness Day - 01 Oct 2014 – Destiny Pharma to attend IDWeek in Philadelphia, PA - 29 Sep 2014 – Obama Administration Takes Actions to Combat Antibiotic-Resistant Bacteria - 04 Sep 14 – Destiny Pharma to attend 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Conference in Washington DC - 04 Aug 2014 – Angel CoFund join UK investors in £2.8m investment for Superbug Killing Company - 01 Jul 2014 – David Cameron says that superbugs can cast “world back into the dark ages of medicine” - 01 Apr 2014 – Destiny Pharma to attend 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Conference in Barcelona, Spain - 01 Jan 2014 – January 2014: ADAPT Act to Spur Antibiotic Development 2013 - 20 Dec 2013 – Destiny Pharma to attend 32nd Annual J.P. Morgan Healthcare Conference, San Francisco - 18 Nov 2013 – 6th European Antibiotic Awareness Day - 07 Nov 2013 – Destiny Pharma to attend BioInfect 2013 Conference - 24 Sep 2013 – Report by CDC details today’s drug-resistant health threats - 19 Sep 2013 – UK Government publish strategy to combat antimicrobial resistance between 2013 and 2018 - 20 May 2013 – Press Release: Part 2 of NIAID-funded US clinical trial of anti-staphylococcal nasal gel XF-73 begins enrollment - 01 Mar 2013 – Chief Medical Officer Dame Sally Davies publishes annual report providing a comprehensive overview of the threat of antimicrobial resistance and infectious diseases - 01 Feb 2013 – New US Therapeutic Guidelines on Antimicrobial Prophylaxis published which recommend that all higher risk surgeries should now decolonise all patients with documented colonisation with S. aureus and not just MRSA - 01 Jan 2013 – US ICU infection rate cut by 44% by Universal bacterial Decolonisation – Hospital Corporation of America (HCA) ICU’s to adopt this regimen during early 2013 - 01 Jan 2013 – Chief Medical Officer Dame Sally Davies says that antibiotic-resistant diseases pose “Apocalyptic” threat and tells MPs that the issue should be added to the UK Government’s national risk register of civil emergencies 2012 - 17 Oct 2012 – National Institutes of Health launch US clinical trial of XF-73, a new anti-Staphylococcal drug - 01 Jul 2012 – Generating Antibiotic Incentives Now (GAIN) Act passed by US Senate on 26th June 2012 - 26 Mar 2012 – Press Release: IND opens for anti-Staphylococcal drug XF-73 and NIAID-funded US clinical trial begins 2011 - 04 Nov 2011 – Press Release: Sir Nigel Rudd to lead company behind MRSA cure Archive 2020 2019 2018 2017 2016 & Prior
